These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 16215448)

  • 1. Cost-effectiveness of bupropion, nortriptyline, and psychological intervention in smoking cessation.
    Hall SM; Lightwood JM; Humfleet GL; Bostrom A; Reus VI; Muñoz R
    J Behav Health Serv Res; 2005; 32(4):381-92. PubMed ID: 16215448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients.
    Van Schayck CP; Kaper J; Wagena EJ; Wouters EF; Severens JL
    Addiction; 2009 Dec; 104(12):2110-7. PubMed ID: 19922576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychological intervention and antidepressant treatment in smoking cessation.
    Hall SM; Humfleet GL; Reus VI; Muñoz RF; Hartz DT; Maude-Griffin R
    Arch Gen Psychiatry; 2002 Oct; 59(10):930-6. PubMed ID: 12365880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of bupropion and nortriptyline for smoking cessation among people at risk for or with chronic obstructive pulmonary disease.
    Wagena EJ; Knipschild PG; Huibers MJ; Wouters EF; van Schayck CP
    Arch Intern Med; 2005 Oct; 165(19):2286-92. PubMed ID: 16246996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results.
    Haggsträm FM; Chatkin JM; Sussenbach-Vaz E; Cesari DH; Fam CF; Fritscher CC
    Pulm Pharmacol Ther; 2006; 19(3):205-9. PubMed ID: 16517193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of clinical smoking cessation interventions in Thailand.
    Tosanguan J; Chaiyakunapruk N
    Addiction; 2016 Feb; 111(2):340-50. PubMed ID: 26360507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
    Hill A
    Tex Med; 2006 Aug; 102(8):50-5. PubMed ID: 17115560
    [No Abstract]   [Full Text] [Related]  

  • 9. Bupropion and cognitive-behavioral treatment for depression in smoking cessation.
    Brown RA; Niaura R; Lloyd-Richardson EE; Strong DR; Kahler CW; Abrantes AM; Abrams D; Miller IW
    Nicotine Tob Res; 2007 Jul; 9(7):721-30. PubMed ID: 17577801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation.
    Quaak M; van Schayck CP; Postma DS; Wagena EJ; van Schooten FJ
    Addiction; 2012 Jan; 107(1):178-87. PubMed ID: 21658141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More on PHARMAC and tobacco control in New Zealand.
    Metcalfe S; Moodie P
    N Z Med J; 2006 Jan; 119(1228):U1837. PubMed ID: 16462938
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial.
    Simon JA; Duncan C; Huggins J; Solkowitz S; Carmody TP
    Nicotine Tob Res; 2009 Jun; 11(6):663-9. PubMed ID: 19395688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
    Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
    Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking cessation interventions for smokers with current or past depression.
    van der Meer RM; Willemsen MC; Smit F; Cuijpers P
    Cochrane Database Syst Rev; 2013 Aug; (8):CD006102. PubMed ID: 23963776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women.
    Revicki DA; Siddique J; Frank L; Chung JY; Green BL; Krupnick J; Prasad M; Miranda J
    Arch Gen Psychiatry; 2005 Aug; 62(8):868-75. PubMed ID: 16061764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varenicline in the management of smoking cessation: a single technology appraisal.
    Hind D; Tappenden P; Peters J; Kenjegalieva K
    Health Technol Assess; 2009 Sep; 13 Suppl 2():9-13. PubMed ID: 19804684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
    Wing VC; Shoaib M
    Psychopharmacology (Berl); 2007 Dec; 195(3):303-13. PubMed ID: 17690868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic considerations in the management of smoking cessation.
    Godfrey C; Fowler G
    Drugs; 2002; 62 Suppl 2():63-70. PubMed ID: 12109937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Smoking Cessation Treatment for Patients With Mental Disorders Using CBT and Combined Pharmacotherapy.
    Loreto AR; Carvalho CFC; Frallonardo FP; Ismael F; Andrade AG; Castaldelli-Maia JM
    J Dual Diagn; 2017; 13(4):238-246. PubMed ID: 28489501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.